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S U M M A R Y
Objectives: To deﬁne acute optic neuritis following infection with chikungunya virus (CHIKV) and to
determine the efﬁcacy of treatment with corticosteroids of acute optic neuritis.
Methods: This was an observational study involving 10 patients, who were conﬁrmed cases of infection
with CHIKV with acute optic neuritis in one or both eyes. A complete ophthalmic examination was
performed in all cases. All 10 patients were treated with intravenous methylprednisolone for 3 days,
followed by oral prednisolone for 2 weeks, thereafter reducing the dose of prednisolone over 1 month.
Results: Of the 10 patients in the study, seven were male and three female. Seven patients had unilateral
optic neuritis and three patients had bilateral optic neuritis. Initial visual acuity in the affected eyes
ranged from perception of light to visual acuity of 6/6. After treatment, nine out of 10 patients improved
to visual acuity of 6/12 or better. Color vision became normal in eight patients in our study. After
treatment, a relative afferent pupillary defect persisted in four patients and six patients had normal
pupils. A statistically signiﬁcant improvement in vision was found after treatment (p  0.001). Visual
ﬁeld (HFA FF 120) examination showed various types of defect. Visual ﬁelds returned to normal in four
patients, while the remaining six patients had persistent diffuse visual ﬁeld defects.
Conclusions: CHIKV infection may cause acute-onset of visual loss due to acute optic neuritis. Prompt
recovery of visionmay follow steroid therapy. Physicians should be aware of the possibility of acute optic
neuritis following CHIKV infection so that a preventable cause of vision loss can be treated effectively.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Chikungunya is an acute febrile syndrome characterized by
high-grade fever with chills, myalgia, headache, photophobia, skin
rash, and severe disabling arthritis.1 Chikungunya fever is most
often a self-limiting febrile illness,1 however recent outbreaks
appear to have been more severe than previous outbreaks, with
more systemic manifestations and even death.2,3 Ocular abnor-
malities described in these recent outbreaks are optic neuritis,
papillitis, neuroretinitis, panuveitis, non-granulomatous anterior
uveitis, and retinitis.4–7
Here we present an observational study of acute optic neuritis
following chikungunya virus (CHIKV) infection during a short
epidemic, over the period from July 12 to August 21, 2007 in the
state of Kerala, southern rural India.* Corresponding author. Tel.: +91 9447134973.
E-mail address: dranooptm@yahoo.co.in (T.M. Anoop).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.10.0042. Methods
Thiswas an observational study involving 10 patientswhowere
conﬁrmed cases of infection with CHIKV with acute optic neuritis
in one or both eyes. The study was conducted in the Department of
Ophthalmology and Internal Medicine, Kottayam Medical College,
Kerala, following the viral fever epidemic, during a 6-week period
from July 12 to August 21, 2007.
A routine hemogram, including total count, differential count,
erythrocyte sedimentation rate, platelet count, and peripheral
blood smear was done. Anti-nuclear antibody, blood culture, Widal
test, Mantoux test, IgM leptospiral antibody, IgM dengue antibody,
test for syphilis, and retroviral antibody tests were also performed.
A complete ophthalmic examination, including best-corrected
visual acuity (BCVA; Snellen chart), color vision (Ishihara
pseudoisochromatic color vision plates), pupillary reaction (RAPD,
relative afferent pupillary defect), and visual ﬁeld (Humphrey ﬁeld
analyzer), as well as intraocular pressure by applanation tonome-
try, indirect ophthalmoscopy of the dilated fundus, slit lamp
biomicroscopy of the anterior and posterior segments, and visual
evoked potentials were performed in all cases. RAPDwas graded asses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Fundus photograph of a 42-year-old woman with acute optic neuritis
following chikungunya fever, showing disc edema.
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constriction followed by greater redilation; grade 2+ is an initial
pupillary stall followed by greater redilation; grade 3+ is an
immediate pupillary dilation; and grade 4+ is no reaction to light
(amaurotic pupil). Fundus photograph of a 42-year-old woman
with acute optic neuritis following chikungunya fever, showing
disc edema is shown in Figure 1.
All patients were diagnosed to have a CHIKV infection based on
typical clinical presentation of acute fever with severe disabling
arthralgia and a positive IgM CHIKV serological test, and negative
test results for dengue, typhoid, malaria, and tuberculosis. A
screening magnetic resonance imaging (MRI) was also performed
in all patients to rule out any form of demyelination.
All 10 patients were treated with intravenous methylpredniso-
lone 1 g/day for 3 days, followed by a daily dose of 1 mg/kg body
weight of oral prednisolone for 2 weeks, thereafter reducing the
dose of prednisolone over 1 month. Blood pressure, body weight,Table 1
Demographic and ocular features of 10 patients with optic neuritis associated with ch
Patient
number,
age/gender
Ocular
symptoms
Ocular
features
Visual
ﬁeld
defect
IgM
CHIKV
Ab test
1, 42/F Defective
vision
Disk edema,
RAPD
Paracentral
scotoma
Positive
2, 45/M Defective
vision
Disc edema,
B/L pupillary
sluggish reaction
Central
scotoma
both eyes
Positive
3, 24/M Defective
vision
Disc edema,
disc hemorrhage,
B/L pupillary
sluggish reaction
Diffuse
(severe)
both eyes
Positive
4, 35/M Defective
vision
Disc edema,
B/L pupillary
sluggish reaction
Diffuse
(severe)
both eyes
Positive
5, 44/M Defective
vision
Disc edema,
RAPD
Centrocecal
scotoma
Positive
6, 38/M Defective
vision
Disc edema,
disc hemorrhage,
RAPD
Diffuse
(severe)
Positive
7, 42/F Defective
vision
Disc edema,
RAPD
Diffuse
(mild)
Positive
8, 31/F Defective
vision
Disc edema,
RAPD
Diffuse
(severe)
Positive
9, 22/M Defective
vision
Disc edema,
RAPD
Diffuse
(severe)
Positive
10, 35/M Defective
vision
Disc edema,
RAPD
Peripheral
constriction
Positive
B/L, bilateral; CF, counting ﬁnger; CHIKV Ab, chikungunya virus antibody; PL, perception o
potential (mean P100 latency, ms).blood sugar, serum electrolytes, and electrocardiography were
recorded before starting therapy. None of our patients had risk
factors like hypertension or diabetes mellitus or a previous history
of visual loss. The patients were treated as inpatients during the
period of intravenous therapy and were discharged over the next 3
days. Patients were followed up at 2, 3, and 4 weeks.
Visual function (color vision, visual ﬁeld, and BCVA) was
compared before and after intravenous methylprednisolone
therapy. Informed consent was obtained from all study patients.
3. Results
Demographic and ocular features of the 10 patients with optic
neuritis associated with CHIKV infection are described in Table 1.
Of the 10 patients in the study, seven were male and 3 female. All
patients in the study were in the age group 22–45 years. All 10
patients in the study series presented with sudden onset decrease
in vision or blurring of vision, which deteriorated over the next few
days. All 10 patients had a history of fever, joint pain, and skin rash
1–6 weeks prior to the onset of defective vision. Among the 10
patients, three had defective vision and pain on ocular movements
in both eyes and seven had complaints only in one eye. None of
these patients had demyelination in the screening MRI.
Seven patients had unilateral optic neuritis and three had
bilateral optic neuritis. The types of optic neuritis in the study
population were: unilateral papillitis (four patients), bilateral
papillitis (three patients), retrobulbar neuritis (one patient),
perineuritis (one patient), and neuroretinitis (one patient).
4. Visual acuity proﬁle of eyes with acute optic neuritis
following chikungunya
Initial visual acuity in abnormal eyes in our study ranged from
perception of light (PL) to visual acuity of 6/6 (Table 1).
After treatment, nine out of 10 patients improved to visual
acuity of 6/12 or better (Table 2). One patient who had an initialikungunya virus infection
VEP Type of
optic
neuritis
Laterality Pre-
treatment
VA
Visual
outcome
(post-treatment
VA)
115 Papillitis Right eye PL+*/6/6 6/6/6/6
110 Papillitis Both eyes 6/12*/6/6* 6/6/6/6
110 Papillitis Both eyes CF2m*/CF3m* 6/12/6/12
130 Papillitis Both eyes 6/36*/6/36* 6/6/6/6
118 Papillitis Right eye 6/36*/6/18 6/18/6/18
110 Neuroretinitis Left eye 6/6/CF1/2m* 6/6/6/6
118 Perineuritis Right eye 6/6*/6/6 6/6/6/6
110 Retrobulbar
neuritis
Right eye 6/60*/6/6 6/6/6/6
110 Papillitis Left eye 6/6/6/36* 6/6/6/6
110 Papillitis Right eye 6/60*/6/6 6/6/6/6
f light; RAPD, relative afferent pupillary defect; VA, visual acuity; VEP, visual evoked
Table 2
Comparison of pre-treatment and post-treatment visual acuity outcome of patients
with chikungunya infection-related acute optic neuritis
Visual acuity Pre-treatment Post-treatment
6/12 2 9
6/18–6/36 3 1
6/60–CF1m 2 0
CF1m–PL+ 3 0
Total number of patients 10 10
CF, counting ﬁnger; PL, perception of light.
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same patient had early cataractous changes in both eyes; BCVA in
the normal eye was 6/18.
5. Color vision outcome
After treatment, color vision became normal in eight patients.
Color vision abnormality persisted in two patients.
6. Pupillary reaction
Before treatment, all 10 patients had pupillary abnormalities –
seven had RAPD and three had bilateral optic neuritis with sluggish
reaction of the pupil. After treatment, RAPD persisted in four
patients, and six patients had normal pupils. A statistically
signiﬁcant improvement in vision was noticed after treatment
(p  0.001).
7. Visual ﬁeld defects
Visual ﬁeld (HFA FF 120) examination showed various types of
defect, including central, centrocecal, and paracentral scotoma and
peripheral constriction. Visual ﬁeld returned to normal in four
patients, while the remaining six patients had persistent diffuse
visual ﬁeld defects.
8. Discussion
Chikungunya virus infection has recently been reported to
cause varied ocular manifestations, like non-granulomatous
anterior uveitis, episcleritis, panuveitis, granulomatous anterior
uveitis, optic neuritis, sixth nerve palsy, retrobulbar neuritis,
retinitis with vitritis, neuroretinitis, keratitis, central retinal artery
occlusion, choroiditis, exudative retinal detachment, and second-
ary glaucoma.4–9 The types of optic neuritis in our study
population were unilateral papillitis, bilateral papillitis, retro-
bulbar neuritis, perineuritis, and neuroretinitis. Patients with optic
neuritis generally present with pain on eye movement associated
with unilateral visual loss, visual ﬁeld defects, and changes in color
perception. The visual loss is progressive and may occur rapidly
over several hours or more slowly over days.
The exact mechanism of optic nerve involvement following
chikungunya fever is unknown.5 The possible causes may be direct
viral involvement and a delayed immune response after a viral
infection. Several characteristics such as delay in onset, partial
recovery of disc changes, bilateral involvement in a few patients,
and good response to corticosteroid therapy indicate the
possibility of an autoimmune mechanism in the pathogenesis of
the disease.5 The onset of visual symptoms a few weeks after
chikungunya fever in our patients favors the hypothesis that the
ocular lesions could be an immune-mediated process rather than a
direct viral infection. The prompt response to steroids also favors
an immune-mediated cause.
In our study, after treatment with intravenous methylprednis-
olone, 12 out of 13 eyes improved to 6/12. One patient had aninitial visual acuity of 6/36, which improved to 6/18, and that same
patient had early cataractous changes in both eyes. The overall
prognosis in terms of visual acuity, color vision, and visual ﬁeld
was good.
Corticosteroid therapy in the form of 3 days of intravenous
methylprednisolone, followed by oral prednisolone in a tapering
dose, could assist in the rapid recovery of visual function in
patients with acute presentation of optic neuritis. In one clinical
series, clinical response to intravenous pulsed dexamethasone led
to rapid recovery of vision and visual function outcome in Indian
patients with acute optic neuritis.10
Simultaneous onset of systemic and ocular disease suggests
direct viral involvement. In contrast to the study byMittal et al., all
10 patients in our study had defective vision 1–6 weeks after the
onset of systemic disease and none had simultaneous systemic and
ocular involvement. Mittal et al. described the mechanism of optic
nerve involvement following CHIKV infection as being direct viral
involvement in 36% and late optic nerve involvement, suggesting a
delayed immune response (post-viral infection) in 64%.5 Cortico-
steroid therapy may lead to rapid recovery of visual function in
patients with acute presentation of optic neuritis, but has no role
when treatment is initiated at a late stage of the disease.5 Mittal
et al. described three patients in whom treatment was initiated 1
month after the onset of visual symptoms for whom there was no
visual improvement. This suggests that corticosteroid therapy has
no role when treatment is initiated at a late stage of the disease. In
our study, all 10 patients presenting with vision loss after 1–6
weeks of systemic disease were immediately started on cortico-
steroid therapy following the documentation of acute optic
neuritis. Since we have no data to suggest the role of corticoster-
oids in patients with delayed presentation (after 6 weeks) of optic
neuritis following CHIKV infection in our study, more clinical
studies are needed to document the role of corticosteroids in late
cases (after 6 weeks) of CHIKV-related optic neuritis.
In conclusion, even though chikungunya infection is a self-
limiting illness, CHIKV infection may cause acute-onset visual loss
due to acute optic neuritis. Prompt recovery of vision may follow
steroid therapy. Physicians should be aware of the possibility of
acute optic neuritis following CHIKV infection so that a prevent-
able cause of vision loss can be treated effectively.
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